The Second Genome team is comprised of veterans in microbiome research and drug discovery.
Peter B. DiLaura, President & CEO
Peter DiLaura was named President and CEO of Second Genome in November 2010. Prior to Second Genome, Peter was the Senior Vice President of Products and Marketing at Ingenuity Systems. Peter joined Ingenuity in 2001, and during his time at Ingenuity was responsible for a variety of roles on the senior management team including business development, global sales and marketing, and corporate strategy. Prior to Ingenuity, Peter held roles at Chemdex/Ventro and IBM. Peter began his career in life sciences as a strategy consultant to the pharmaceutical and biotechnology industries in the New York office of The Wilkerson Group. Peter received a BS in Economics from the Wharton School at the University of Pennsylvania.
Peter S. DiStefano, SVP Research & Development
Peter DiStefano has over 25 years of experience in pharma and biotech, holding several positions in drug discovery and development. Prior to joining Second Genome, he was Chief Scientific Officer and Sr. VP of R&D at Elixir Pharmaceuticals. At Millennium Pharmaceuticals, he headed the psychiatric disease and pain programs as Sr. Director of Neurobiology. He currently serves on the Board of Directors at Acylin Therapeutics, a biotech start-up company in Seattle, WA focused on cancer therapeutics which he founded in 2010. Dr. DiStefano received his Ph.D. in Pharmacology from Upstate Medical Center in Syracuse. He did his post-doctoral training in Pharmacology at Washington University in St. Louis. He has co-authored over 100 manuscripts, reviews and book chapters and is a co-inventor on 12 issued patents.
Mohan S. Iyer, SVP Corporate Development
Mohan Iyer brings 25 years of experience in the healthcare sector in a range of functions. Most recently, he was Chief Financial and Business Officer of Tethys Bioscience, a venture backed company dedicated to the discovery, development and commercialization of biomarkers for chronic metabolic diseases. Previously, he was Managing Director in the merchant banking group at Burrill & Company where he advised biotech companies on partnering and M&A transactions. He also spent seven years as a member of the executive team at diaDexus where he played a key role in the commercialization of a novel diagnostic product for cardiovascular risk assessment. He holds a BS in Chemical Engineering from the University of Tennessee, an MS in Biomedical Engineering from Duke University and an MBA from Yale University.
Todd Z. DeSantis, Co-Founder & Head of Bioinformatics
Todd DeSantis has more than a decade of experience designing and implementing bioinformatics pipelines for analyzing microbial population dynamics. At Lawrence Berkeley National Laboratory he architected novel microbiome assays and analysis pipelines as a Molecular Microbial Ecology Software Developer. He also designed and manages Greengenes, an international effort to catalog global microbial diversity that provides microbial ecologists with resources and online tools for DNA quality assessment, alignment and classification. Todd also served as an analyst for the NIH Human Microbiome Project and has authored over 50 manuscripts. At Second Genome, he manages all bioinformatics work and oversees the planning, performance and interpretation of projects and the production of data reports.